Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HY-1010
- Development stage
- Unknown
- Lead developer
- Sichuan Huiyu Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
HY-1010 is an investigational topical spray formulation developed by West China Hospital of Sichuan University for the treatment of androgenetic alopecia (AGA). The drug is currently being evaluated in a clinical trial (ChiCTR2500096521) involving healthy adult men with Hamilton-Norwood grade 3–5 hair loss. The study aims to assess the safety and efficacy of nine different spray formulations of HY-1010 over a 16-week period, focusing on improvements in hair density and local hair counts. As a topical treatment, HY-1010 is designed to address the miniaturization of hair follicles characteristic of AGA and promote hair regrowth.
- Other names
- HY-1010HY1010HY 1010
Beyond the preview
Go deeper on HY-1010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HY-1010.